VOQUEZNA is a first-in-class PCAB for GERD
In a phase 1, open-label, crossover study with 44 healthy volunteers receiving VOQUEZNA 20 mg once daily,*,†
VOQUEZNA has been shown to provide rapid, potent, and durable acid suppression
reaching pH >4 within 4 hours
with a mean pH of 4.6
acid suppression over 24 hours
VOQUEZNA rapidly achieved a pH >4
The clinical significance of quantitative differences in mean intragastric pH has not been established.
| MEAN INTRAGASTRIC pH | VOQUEZNA 20 mg | LANSOPRAZOLE 30 mg |
|---|---|---|
| Day 1 | 4.6 | 2.8 |
| Day 7 | 5.9 | 3.8 |
| The clinical significance of quantitative differences in mean intragastric pH has not been established. | ||
| PERCENTAGE OF A 24-HOUR PERIOD WITH A pH >4 MAINTAINED | VOQUEZNA 20 mg | LANSOPRAZOLE 30 mg |
|---|---|---|
| Day 1 | 62% | 23% |
| Day 7 | 88% | 42% |
| The clinical significance of quantitative differences in mean pH holding‑time ratio has not been established. | ||
*Healthy volunteers were randomized to 7 days of vonoprazan 20 mg once daily (QD) followed by lansoprazole 30 mg QD, or the reverse, separated by a ≥7‑day washout. Subjects fasted and received study drug each morning. On days 1 and 7 of each 7‑day period, breakfast was held and subjects received standardized meals 4‑ and 9‑hours post‑dose, and a snack 12‑hours post‑dose.1
†20 mg daily is the approved dose for healing of Erosive GERD. Approved dose for maintenance of healing of Erosive GERD and Non-Erosive GERD is 10 mg once daily.2
| PRODUCT ATTRIBUTES | VOQUEZNA | LANSOPRAZOLE |
|---|---|---|
| Mean half-life | 7.7-7.9 hours (10 mg and 20 mg, respectively) | 1.5 hours |
| Acid activation | Does not require activation by acid | Requires activation by acid |
| Dosing with food | Can be taken with or without food | Needs to be taken before a meal |
| Interaction with active acid pumps | Noncovalent and reversible | Covalent and irreversible |
| The clinical significance of these mechanistic differences has not been established. | ||